by MM360 Staff | Jun 2, 2025 | Uncategorized
Source: CureToday articles Dr. Sarah Sammons discusses side effects associated with RLY-2608, and how it effects patients with HR-positive, HER2-negative advanced breast cancer. Read More
by Andrew (Drew) Rhoades; Francesca Castro, MS, RD, CDN | Jun 2, 2025 | Uncategorized
ORLANDO — A high-fiber, plant-based dietary intervention and nutritional counseling improved several risk factors for multiple myeloma, a study presented at the annual NUTRITION meeting showed.“Our study shows the power of nutrition in the preventive setting and...
by MM360 Staff | Jun 2, 2025 | Uncategorized
Source: CureToday articles Imlunestrant alone or in combination with Verzenios improved patient-reported outcomes in ER+, HER2– advanced breast cancer following endocrine therapy. Read More
by MM360 Staff | Jun 2, 2025 | Uncategorized
Source: CureToday articles Dr. Alexander Chehrazi-Raffle discusses findings from the phase 3 TiNivo-2 trial, designed to evaluate treatment with Fotivda in patients with metastatic renal cell carcinoma. Read More
by MM360 Staff | Jun 2, 2025 | Uncategorized
Source: CureToday articles As a cancer survivor I explain the importance of looking forward to life. Read More
by MM360 Staff | Jun 2, 2025 | Uncategorized
Source: CureToday articles Adding Enhertu to Perjeta improved time without cancer growth versus standard care in advanced HER2-positive breast cancer, as per data from DESTINY-Breast09. Read More